Galectin Therapeutics Inc. (NASDAQ:GALT) has been assigned a consensus broker rating score of 3.67 (Sell) from the three brokers that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong sell recommendation and two have assigned a hold recommendation to the company.
Analysts have set a 1 year consensus price objective of $1.12 for the company and are anticipating that the company will post ($0.17) earnings per share for the current quarter, according to Zacks. Zacks has also given Galectin Therapeutics an industry rank of 90 out of 265 based on the ratings given to its competitors.
A number of analysts recently commented on GALT shares. Zacks Investment Research cut shares of Galectin Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday. FBR & Co set a $2.00 price target on shares of Galectin Therapeutics and gave the company a “hold” rating in a research note on Monday, November 14th. Finally, HC Wainwright cut shares of Galectin Therapeutics from a “buy” rating to a “neutral” rating and dropped their price target for the company from $8.00 to $1.50 in a research note on Thursday, September 29th.
Shares of Galectin Therapeutics (NASDAQ:GALT) opened at 1.02 on Monday. The firm’s 50 day moving average is $0.98 and its 200-day moving average is $1.31. The company’s market cap is $29.98 million. Galectin Therapeutics has a 1-year low of $0.49 and a 1-year high of $3.05.
Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in Galectin Therapeutics by 0.4% in the second quarter. Vanguard Group Inc. now owns 606,537 shares of the company’s stock valued at $892,000 after buying an additional 2,490 shares in the last quarter. D.A. Davidson & CO. boosted its stake in Galectin Therapeutics by 5.9% in the third quarter. D.A. Davidson & CO. now owns 602,731 shares of the company’s stock valued at $681,000 after buying an additional 33,382 shares in the last quarter. Advisor Group Inc. boosted its stake in Galectin Therapeutics by 3.8% in the third quarter. Advisor Group Inc. now owns 413,125 shares of the company’s stock valued at $467,000 after buying an additional 15,200 shares in the last quarter. Courage Capital Management LLC purchased a new stake in Galectin Therapeutics during the third quarter valued at about $147,000. Finally, Benchmark Capital Advisors boosted its stake in Galectin Therapeutics by 98.3% in the third quarter. Benchmark Capital Advisors now owns 118,200 shares of the company’s stock valued at $134,000 after buying an additional 58,600 shares in the last quarter. Institutional investors and hedge funds own 10.18% of the company’s stock.
About Galectin Therapeutics
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
Get a free copy of the Zacks research report on Galectin Therapeutics (GALT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com